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Circulating anti-entactin antibodies in patients with glomerulonephri-
tis. Sera from 305 consecutive patients in a renal biopsy series were
analyzed for the presence ofanti-entactin antibodies by ELISA. Of
these patients, 59% had primary glomerulonephritis, 21% had second-
ary glomerulonephritis, while 20% had other ñephropathies (non-
inflammatory conditions like amyloidosis; diabetic nephropathy, neph-
roscierosis, etc.). Forty-one of these patients (13.4%) were positiye for
IgG/IgM antibodies against entactin; 60% of them had primary glomer-
ulonephritis, 35% had secondary glomerulonephritis, while the remain-
ing 3 patients had other nephropathies. Fifteen (70%) of the 23 patients
with primary glomerulonephritis had proliferative glomerulonephritis
(PGN), whereas 13 (87%) of the 15 patients with secondary glomerulo-
nephritis were due to systemic connective tissue diseases (SCTD); 7
due to SLE, 4 due to SLE like SCTD and two due to other SCTD. There
was a peak of incidence corresponding tO the group aged 18 to 30 years.
A majority of these patients (12 of the total 17) had primary glomeru-
lonephritis andwere associated with nephrotic or subnephrotic grade
proteinuria, poorly or nonresponsive to immunosuppressive treatment
and associated, in several cases, with progressive deterioration of renal
function. In addition, there was a tendency to another peak in the age
group 51 to 60 years. Most of these patients (6 of the total 8) had
glomerulonephritis secondary, mainly, to SLE or SLE like SCTD with
milder degree of proteinuria and better preserved renal functions.
Anti-entactin antibodies were not found in certain glomerulonephritides
like IgA nephropathy and those secondary to systemic vasculitides and
in control subjects (healthy subjects, and patients with a variety of
non-renal disorders including inflammatory diseases). There was a
significant correlation between the presence of circulating
antibodies and the deposition of corresponding class of immunoglobulin
along the glomerular basement membrane. In addition, a significant
correlation between the absence of immune deposits and negative
results for anti-çntactin antibodies by ELISA was also observed. Our
observations suggest that anti-entactin antibodies are associated with
certain definite categories of glomerUlonephritides in human beings and
may well be involved in their immunopathogenesis.
Immunological mechanisms play a major role in the patho-
genesis of glomerulonephritides in human beings [1—3]. Immune
complex and anti-glomerular basement membrane (anti-GBM)
nephritis are the two major categories of glomerulonephritides
classified on the basis of their possible underlying immuno-
pathogenetic processes [4]. The classical anti-GBM nephritis in
human beings (Goodpasture syndrome) is a rare but a severe
progressive renal disease with an extremely high mortality if left
untreated [5—7]. It consists of nephritis (most often with abun-
dant crescents), with or without pulmonary hemorrhage, and
linear deposit of IgG along the GBM as seen by direct immu-
nofluorescence [8]. The antibody binding epitope involved is
located at the noncollagenous globular domain (NC!) of the a3
chain of collagen IV [9—12]. A few earlier studies have hinted a
possible role of other GBM antigens (non-Goodpasture GI3M
antigens) in the pathogenesis of glomerulonephritis in humans
[7, 13—16]. Similarly, several glomerular antigens have been
described in experimental nephrotoxic nephritis in animals
[17—23]. However, the involvement of auto-antibodies to gb-
merular antigens other than the Goodpasture antigen in the
pathogenesis of anti-GBM nephritis in humans still remains
undefined.
Recently, a study conducted at our department showed that
more than 40% of the patients admitted for investigation of
glomerubonephritides have serum IgG, 1gM and/or IgA antibod-
ies reacting with the antigens present in crude 6 M guanidine-
HC1 extract of GBM [24], Most of the patients with IgA
antibodies to the crude guanidine extract were found to have
IgA nephropathy and possessed circulating IgA-fibronectin
complexes [16, 24]. However, the specificity of IgG/IgM anti-
bodies to the crude extract remained unknown. Immunoblotting
studies utilizing several sera containing these antibodies e-
vealed that the major activity in many cases was in the region of
150 kD of the guanidine extract. This prompted us to isolate the
proteins in this region from the crude 6 M guanidine-HCI extract
of GBM. In this process, we identified entactin/nidogen, a 150
kD sulfated glycoprotein component of GBM as a possible
autoantigen in the pathogenesis of non-Goodpasture anti-GBM
glomerulonephritis in human beings [25]. About 30% of the sera
with antibodies to the crude guanidine extract had IgG/IgM
antibodies to entactin. In the present study, we have analyzed
sera from 305 consecutive patients in a renal biopsy series for
the presence of anti-entactin antibodies. An attempt has also
been made to determine the pattern of distribution of anti-
entactin antibodies among different glomerubonephritides and
their possible correlation with the etiological factors, morpho-
logical and clinical features, the severity and the progression of
the disease.
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Methods
Selection of patients
Sera from 305 consecutive patients from 1982 onwards, who
had come to the nephrology clinic for investigations of glomer-
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ulopathies and interstitial nephropathies and who subsequently
had renal biopsy, were screened for anti-entactin antibodies.
Their sera were sampled at the time of renal biopsy and stored
at —24°C until analyzed. In addition, the following control
groups were also included:
1) One hundred and fifty sera from healthy blood donors.
2) Forty-two sera from patients with complicated pregnancies
which included four patients with accidental hemorrhage,
one patient with placenta previa, one patient with thrombo-
sis, one patient with oligohydramnios, two patients with
multiple pregnancies, three with premature leak, five pa-
tients with gestational diabetes, two patients with insulin
dependent diabetes, four patients with pre-eclampsia, five
patients with high blood pressure, six patients with intra-
uterine growth retardation, three patients with bad obstetric
history, one patient with anemia and one post-mature preg-
nancy. All of them had normal serum creatinine. None of
them had any significant proteinuria or hematuria.
3) Nineteen sera from patients with bronchopneumonia. Caus-
ative organisms could be detected in only three of them (two
had pneumococci and one had H. influenza). None of them
had any apparent features of renal involvement.
Morphological classification of glomerulonephritis
Glomerulonephritides were morphologically classified ac-
cording to the WHO classification of glomerular disease [26]. In
addition IgA nephropathy was classified as a separate group
based upon the immunofluorescence findings of a florid depo-
sition of IgA antibodies in the mesangium [27].
Clinical classification of glomerulonephritis
Patients were broadly classified into two groups: 1) those
with proteinuria and/or hernaturia with active urinary sediment
were classified as glomerulonephritis and 2) those with no
evidence of glomerulonephritis were classified as having other
nephropathies which included amyloidosis, diabetic nephrop-
athy, focal and diffuse nephrosclerosis, tubulointerstitial ne-
phritis and a few unclassifiable nephropathies. Patients with
glomerulonephritis were further classified as those with primaty
or secondary glomerulonephritis depending upon the absence
or the presence of extrarenal features that could be associated
with glomerulonephritis. Most patients with secondary glomer-
ulonephritis had either systemic connective tissue disorders
(SCTD) or systemic vasculitides. Among SCTD, those who
qualified the modified American Rheumatology Association
(ARA) [281 as well as the weighted criteria [291 were labeled
SLE. Those who had systemic lupus erythematosus (SLE) like
disease with positive anti-nuclear antibody (ANA) titers but not
fulfilling the previously mentioned criteria were labeled as SLE
like SCTD. The diagnosis of rheumatoid arthritis was based
upon ARA criteria for rheumatoid arthritis [30] while that of
systemic vasculitis was essentially as described by Fauci and
coworkers [31, 32].
Class jfication of proteinuria
Proteinuria was classified as follows:
Nephrotic. Serum albumin <25 glliter; albumin clearance/
creatinine clearance x 1000> 1.0; and/or urinary albumin >3.0
g/liter.
Subnephrotic. Serum albumin 25 to 36 g/liter; albumin clear-
ance/creatinine clearance x 1000 between 0.3 and 1.0; and/or
urinary albumin 1.0 to 3.0 g/liter.
Mild. Serum albumin >36 g/liter; albumin clearance/creati-
nine clearance x 1000 between 0.1 and 0.3; and/or urinary
albumin 0.3 to 1,0 g/liter.
Impairment of renal function
Patients were considered to have impaired renal function
when serum creatinine values were more than 120 moL/1iter.
Examination of renal biopsies
Up to December 1984, renal biopsies for light microscopy,
immunofluorescence microscopy and electron microscopy were
examined by Dr. Claus Brun, Dr. Svend Larsen, and Dr. Finn
JØrgensen at Kommunehospitalet, Copenhagen, Denmark, and
thereafter at the Department of Pathology, University Hospital
of Lund, Sweden by Dr. Hans Henriksson and Dr. Per Alm.
Routine laboratory investigations
Biochemical, bacteriological and serological investigations
were performed by standard techniques at the hospital.
Analysis of anti-entactin antibodies
Isolation of entactin. Entactin was isolated essentially as in
our earlier study [25]. Briefly, glomeruli were isolated from
bovine kidneys by sieving procedures as described elsewhere
[33]. Isolated glomeruli were sonicated to remove the cellular
debris and obtain GBM. GBM was then briefly homogenized in
ten volumes of 6 M guanidine hydrochloride, 0.05 M Tris-HCI,
pH 7.5, containing protease inhibitors [25]. The extraction was
performed overnight at 37°C with continuous stirring. The
extract was clarified by centrifugation at 100,000 x g for 60
minutes and the extraction procedure was repeated again with
the pellets. The two extracts were then pooled. One hundred
and fifty milliliters of the guanidine extract were dialyzed
against three changes of 10 volumes of 6 M urea, 0.05 M
Tris-HC1, pH 8.4, containing protease inhibitors [25] and passed
over a DEAE Sephacel anion exchange column (Pharmacia,
Uppsala, Sweden) equilibrated with the same buffer. The bound
proteins were eluted by a linear salt gradient (0 to 0.75 M NaCl)
and the fractions were analyzed by SDS-PAGE on 6 to 25%
gradient polyacrylamide slab gels [34] and by ELISA utilizing
rabbit anti-entactin anti-serum [35]. Fractions containing entac-
tin were pooled and concentrated to 15 ml by YM1O filter
(Amicon, Danvers, Massachusetts, USA) and applied to a
Sephacryl S-300 gel filtration column (Pharmacia) equilibrated
with 6 M guanidine-HC1, 0.05 M Tris-HCI, pH 7.5. The fractions
containing entactin were pooled and concentrated to 2 ml,
dialyzed against three changes of 6 M urea, 0.02 M sodium
acetate, pH 4.8 containing protease inhibitors and chromato-
graphed on a Mono S cation exchange FPLC column (Pharma-
cia) equilibrated with the same buffer. The bound proteins were
eluted by a linear salt gradient (0 to 1 M NaCI). The fractions
containing entactin were rechromatographed on a Sephacryl
S-300 column to obtain pure entactin.
Sandwich ELISA. Antibodies to entactin in sera from various
patients, normal sera and the reference serum (rabbit anti-
entactin anti-serum) were tested by sandwich ELISA as fol-
lows: Microtiter plates (Nunc, Roskilde, Denmark) were coated
with entactin (145 nglml in 0.05 M sodium carbonate, pH 9.5;
200 1.d in each well) and incubated overnight at room tempera-
ture. Plates were washed three times with 0.9% NaCI, 0.05%
Tween 20 between each steps. Sera (200 d) diluted 1:20 in
PBS-BSA (0.05 M sodium phosphate, pH 7.4, 0.15 M NaCI,
0.05% Na azide, 0.05% Tween 20, 2 mg/mi BSA) were added to
each well and incubated for one hour at room temperature.
Anti-human IgG/JgM/IgA-aikaline phosphatase was used for
human sera and anti-rabbit IgG-alkaline phosphatase conjugate
for the reference serum (Orion diagnostics, Esbo, Finland)
(1:1000 in PBS-BSA; 200 d each well). The plates were
incubated for one hour. Enzyme activity was determined using
p-nitrophenyl phosphate (Sigma Chemical Co., St. Louis, Mis-
souri, USA) at 1 mg/mi in 1 M diethanolamine buffer, pH 9.5 as
the substrate (200 tl in each well). The absorbance was read at
zero time and after 30 minUtes in a Multiscan microtiter plate
reader (Flow Laboratories, Lugano, Switzerland). The zero
value was subtracted from the final readings. Absorbance
readings >2 SD above the average absorbance of the normal
sera analysed in the same way were considered positive.
Statistical methods
Statistical analysis of the data was done utilizing Chi square
one sample and k sample tests, Chi square tests for binomial
distribution with Yates' correction and Fisher's exact probabil-
ity test [36, 371. P values less than 0.05 were considered
significant.
Results
Sera from a consecutive series of 305 adult patients, who had
undergone a renal biopsy, were analyzed for presence of
IgG/IgA/IgM antibodies against entactin. Their features are
summarized as fOllows.
Features of the 305 patients examined for anti-entactin
antibodies
Age and sex distribution. Apart from a few patients in the
extreme old age group, the patients were almost uniformly
distributed among the different age groups (Fig. 1). There was a
slight male preponderance which was more marked in patients
over the age of 40 years.
Morphological lesions. Different glomerular lesions based
upon light microscopy and immunofluorescence findings are
summarized in Table 1. Approximately one-third (110 patients)
had proliferative GN, 11 to 13% each had igA nephropathy and
extracapillary GN, 6 to 7% each had membranous GN, unclas-
sifiable GN and amyloidosis, while 4 to 5% each had minimal
change glomerulopathy, mesangiocapillary GN and glomerulo-
sclerosis. Seven patients (2.5%) had tubulointerstitial nephritis
while about 5% had miscellaneous lesions..
Clinicopathological diagnosis. Of the 305 patients examined,
179 (59%) had primary glomerulonephritis, 66 (1%) had sec-
ondary glomerulonephritis while the remaining 60 (20%) had
other nephropathies (Table 2). The distribution of various
morphological lesions among primary GN is shown in Table 2.
In essence, proliferative GN was most frequent (42%), followed
by IgA nephropathy (22%), while 10% each had membranous
GN and unclassifiable GN, and the remaining 15% were distrib-
Fig. 1. Age and sex distribution of (A) the 305 patients examined for
anti-entactin antibodies and (B) patients positive for anti-entactin
antibodies. The two distributions differed significantly from each other( = 13.72; P < 0.01). Symbols are: (0) females; () males.
uted among mesangiocapillary GN, extracapillary GN, minimal
change nephropathy and Goodpasture syndrome.
About 9G% of the secondary giomerulOnephritides were
shared equally between systemic vasculitides and systemic
connective tissue diseases (SCTD) while eight patients (10%)
had Henoch Schonlein purpura with nephritis. Among systemic
connective tissue disorders 11 of the total 29 patients (40%)
fulfilled the modified ARA and the weighted criteria for the
diagnosis of SLE. The remaining 18 (60%) patients were further
classified into rheumatoid arthritis, SLE-like SCTD (connective
tissue diseases resembling SLE and with positive ANA but not
fulfilling the above-mentioned criteria for the diagnOsis of SLE)
and other SCTD The various morphological lesions among
secondary glomerulonephritis are summarized in Table 3. To
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Table 1. Glomerular morphology in the 305 patients examined
those positive for anti-entactin antibodies
and in
Total Anti-entactin positive cases
Diagnosis cases 1gM IgO Both Total %
Proliferative GN 110 16 3 3 22 20
IgA nephropathy 39 1 0 0 1 2.5
Extracapillary 32 3 1 0 4 12
GN (>50%
crescents)
Membranous GN 22 2 0 0 2 9
Mesangio- 11 0 3 0 3 25
capillary GN
Minimal change 12 0 0 0 0 0
GN
Unclassified GN 19 2 1 0 3 15
Amyloidosis 21 0 0 0 0 0
Tubulointerstitial 7 2 0 0 2 25
nephritis
Nephrosclerosis 15 2 0 0 2 13
Miscellaneous 17 1 1 0 2 11
Total 305 29 9 3 41 13.5
Table 2. Clinicopathological diagnosis in the 305 patients examined
and in those positive for anti-entactin antibodies
Diagnosis
Total
cases
Ant1-entactin pa
cases
sitive
1gM IgG Both Total %
Primary glomerulonephritides
Proliferative ON 76 12 2 1 15 20
Unclassified ON 16 2 0 0 2 12.5
IgA nephropathy 39 1 0 0 1 2.5
Membranous ON 19 2 0 0 2 10
Extra-capillary GN (>50% 7 1 0 0 1 14
crescents)
Goodpasture syndrome 4 0 0 0 0 0
Mesangio-capillary ON 9 0 2 0 2 20
Minimal change ON 8 0 0 0 0 0
Secondary
glomerulonephritides
SLE 11 3 2 2 7 64
Other systemic connective 18 4 2 0 6 25
tissue diseases
Systemic vasculitides 29 2 0 0 2 7
Henoch Schönlein disease 8 0 0 0 0 0
Other glomerulopathies
Alport syndrome 1 0 0 0 0 0
Amyloidosis 21 0 0 0 0 0
Nephrosclerosis 9 0 0 0 0 0
Focal segmental sclerosis 3 0 0 0 0 0
Tubulointerstitial nephritis 6 1 0 0 1 17
Miscellaneous 21 1 I 0 2 10
Total 305 29 9 3 41 13.5
sum up, 29 patients (45%) had proliferative ON, 23 (35%) had
extracapillary GN while the remaining 14 patients (20%) had
other morphological lesions (Table 3).
There were altogether 46 patients with rapidly progressive
glomerulonephritis in primary and secondary glomerulonephrit-
ides.
The group with other nephropathies included amyloidosis,
focal and diffuse glomerular sclerosis, diabetic nephropathy,
tubulointerstitial nephritis and unclassifiable glomerulopathies.
Table 3. Renal morphology in patients with secondary
glomerulonephritides
Anti-entactin
Renal morphology
Total
cases
positive cases
1gM IgG Both Total
Proliferative GN 29 4 1 2 7
Extra-capillary ON (>50% 23 2 1 0 3
crescents)
Membranous GN 2 0 0 0 0
Unclassifiable ON 2 0 1 0
Mesangiocapillary GN 2 0 1 0
Olomerulosclerosis 3 1 0 0
Tubulointerstitial nephritis 2 1 0 0
Normal 3 1 0 0 1
Total 66 9 4 2 15
Analysis of anti-entactin antibodies
Anti-entactin antibodies were analyzed by a solid phase
immunoassay (ELISA) using purified bovine glomerular entac-
tin as the coat. Forty-one (135%) of the 305 patients examined
were found to have IgM/IgO or both antibodies to entactin (Fig.
2). Interestingly, none of them had IgA anti-entactin antibodies.
Among the control groups, none of the normal sera examined
showed any anti-entactin antibodies, whereas one each among
patients with pneumonia and complicated pregnancies were
found to be positive. Both of them had low titers of anti-entactin
antibodies.
The specificity of this assay for anti-entactin antibodies has
been shown in our previous study [25] in an inhibition ELISA
where entactin was able to inhibit these antibodies while NC1
was not. Furthermore, most of the patients with glomerulone-
phritis were tested for antibodies against the NCI domain of
bovine type IV collagen and were found to be negative [38J.
This indicates that the antibodies against entactin found in
patients with glomerulonephritis are not non-specifically di-
rected against bovine proteins. Addition of BSA in the buffer
used for dilution of sera further reduces the possibility of
non-specific reaction against bovine proteins.
Additionally, proteins from bovine origin may possess Oal a
1,3 Gal epitope which is not found in humans, although most
humans possess natural IgO antibodies against this epitope. It
could thus be possible that anti-entactin antibodies that we
measure are actually anti-Gal a 1,3 Oal antibodies. However,
this possibility was ruled out in our previous study [25J.
Features of the patients positive for anti-entactin antibodies
Age and sex distribution. The age distribution of these
patients was significantly different from the overall distribution
of the 305 patients studied ( = 13.72; P < 0.01). Compared to
the overall distribution, patients with anti-entactin antibodies
were significantly overrepresented in the 18 to 30 years age
group ( 12.09; P < 0.001). The positive cases were also
overrepresented in another age group (51 to 60 years); this
overrepresentation was, however, not statistically significant.
There was no overall preponderance of any sex, but females
outnumbered males by 2: 1 in the age group 18 to 30 years (Fig.
1).
Proteinuria and renal function. Nephrotic or sub-nephrotic
grade proteinuria was observed in 27 (66%) patients with
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anti-entactin antibodies and was non-responsive to steroids or
immunosuppressive treatment in 14 of them. Eight of these
non-responsive patients were in the age group of 18 to 30 years
(Table 4). In addition, 15 of the 27 proteinuric patients had
deterioration of renal function despite treatment. Eight of them
belonged to the age group 18 to 30 years (Table 4). To sum up,
the majority of poorly responsive proteinuric patients with renal
function deterioration were in the age group 18 to 30 years (Fig.
3).
There was no correlation between the degree or progression
of proteinuria or deterioration of renal function and the titer or
the class of anti-entactin antibodies (data not shown).
Extra-renal features. Twenty of the 41 patients with anti-
entactin antibodies had extrarenal features (Table 5). Females
outnumbered males by the ratio of 5:2. A majority of patients
with extra-renal features were relatively old (average age 48
years, median age = 52 years) with milder derangement of renal
functions. In contrast to the overall figure of about 35%, only 5
patients with extra-renal features had progressive proteinuria
and renal function deterioration. About two-thirds of them (13
patients) had SCTD, mainly SLE or SLE-like disease, while
five of them (25%) had primary glomerulonephritis with extra-
renal features like thyroid involvement, presence of anti-thy-
roid antibodies, deranged liver function tests or gastrointestinal
features like ulcerative colitis or Crohn's disease. There was no
correlation between the presence of extra-renal features and the
titer or the class of anti-entactin antibodies (data not shown).
Incidence of primary and secondary glomerulonephritis in
patients with anti-entactin antibodies. The distribution of pa-
tients with anti-entactin antibodies among primary and second-
ary glomerulonephritides was significantly different from the
overall distribution of the 305 patients ( 6.52; P < 0.05).
Twenty-three (56%) of the anti-entactin positive patients had
primary glomerulonephritis, 15 had secondary glomerulone-
phritis while the remaining 3 had other nephropathies (Table 2).
Primary glomerulonephritis was more common in relatively
younger patients with a single peak of incidence (12 patients =
52%) corresponding to the age group 18 to 30 years. On the
contrary, secondary glomerulonephritis had a predilection for
two age groups: one (5 = 33%) corresponding to the age group
18 to 30 years and the other (6 40%) corresponding to the age
group 51 to 60 years. This difference of distribution of primary
and secondary glomerulonephritis between the two age groups
was statistically significant (P = 0.023; Fig. 4). Furthermore, 19
(80%) patients with primary glomerulonephritis were less than
50 years of age whereas 8 (54%) patients with secondary
glomerulonephritis were over 50 years of age ( = 6.33, P <
0.05).
Morphological lesions in patients with anti-entactin antibod-
ies. There was a significant difference in the distribution of
various morphological lesions among patients with anti-entactin
antibodies compared to their overall distribution in 305 patients( = 4.02, P < 0.05; Table 1). Proliferative GN was the single
most common morphological lesion among patients with anti-
entactin antibodies irrespective of the aetiological factors (22 of
41 = 53%) while the other morphological types shared the
remaining 47% cases ( = 5.51, P < 0.05).
Clinicopathological diagnosis in patients with anti-entactin
antibodies. The distribution of primary and secondary GN and
other nephropathies among patients with anti-entactin antibod-
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Fig. 2. Circulating 1gM (A) and lgG (B) anti-entactin antibodies in
patients with glomerulonephritis. Three hundred and five sera from
patients with various types of primary and secondary glomerulonephrit-
ides were analysed for the presence of anti-entactin antibodies. The
results are summarized in Table 2. No correlation was observed
between the class or titre of anti-entactin antibodies and the etiological
factors, clinical or morphological features, severity and progression of
disease. (- - - -) represents the upper limit of the normal values.
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Table 4. The clinical course in patients with anti-entactin antibodies in the age group 18 to 30 years
Age and
sex
Morphological
diagnosis Clinical diagnosis Proteinuria
Progression
of proteinuria
Deterioration
of RF
23F Proliferative GN Proliferative GN Nephrotic Yes Yes
21F Proliferative GN Proliferative GN Sub-nephrotic No Yes
30F Proliferative ON Proliferative ON Nephrotic Yes Yes
29M Proliferative GN Proliferative GN Sub-nephrotic Yes Yes
19F Proliferative ON Proliferative GN Sub-nephrotic Yes Yes
22M Proliferative GN Proliferative GN Nephrotic Yes No
23M Proliferative GN Proliferative GN Sub-nephrotic No Yes
26M Proliferative ON Proliferative ON Sub-nephrotic Yes Yes
21M Proliferative ON Proliferative ON Nephrotic No No
24M Proliferative ON Proliferative ON Nil No No
18F Proliferative ON Proliferative GN Nil No No
26F Mesangiocapillary ON Mesangiocapillary ON Sub-nephrotic Yes Yes
24F Unclassified ON SLE Sub-nephrotic No No
23F Mesangiocapillary ON SLE Nil No No
30F Proliferative ON SLE Sub-nephrotic No No
21F Proliferative ON SLE Sub-nephrotic No No
28F Extracapillary ON SCTD-SLE-like Sub-nephrotic Yes No
Fig. 3. Progression of proteinuria and progressive deterioration of
rena/function (RF) in patients with anti-entactin antibodies. Symbols
are: (0) deterioration of RF alone; () progressive proteinuria alone;(•) progressive proteinuria and RF deterioration.
ies differed significantly from their overall distribution in the 305
patients ( = 6.52; P < 0.05; Table 2). Proliferative GN was the
most common type of primary glomerulonephritis among pa-
tients with anti-entactin antibodies (15 of 23 =65%) while the
other types formed only minor groups (g2 = 4.58, P < 0.05).
SCTD was the major cause of secondary glomerulonephriti-
des among patients with anti-entactin antibodies (13 of 15 =
85%); in contrast only two patients had systemic vasculitis (P =
0.002). Furthermore, compared to their overall distribution,
there was a significant overrepresentation of SCTD among
anti-entactin positive patients ( = 14.68, P < 0.001; Fig. 4).
SLE (7 of 13 = 54%) and SLE-like SCTD (4 of 13 = 31%)
constituted the bulk of cases among SCTD in anti-entactin
positive cases, and both were significantly overrepresented
among the positive patients in comparison to their overall
distribution in the 305 patients (k = 10.69, P < 0.01 and P =
0.042 respectively).
Immunofluorescence findings. Results of direct immunofiuo-
rescence staining of the kidney biopsy specimens were avail-
able in 37 of the 41 patients with anti-entactin antibodies. Only
one patient had negative immunofluorescence. In all other
patients with anti-entactin antibodies, a granular pattern of
deposition of immunoglobulins along GBM was observed. In
addition, in some cases mesangial deposits were also observed
but they never occurred exclusively. Complement deposition
was also observed but always together with immunoglobulins.
C3 deposits were observed in 27 patients, C4 in seven patients
while C lq in four patients. The latter included two patients with
SLE, one with membranous nephropathy and one with prolif-
erative glomerulonephritis.
In 30 (82%) of the 37 positive cases with immunofluorescence
findings, the deposition of IgG or 1gM on immunofluorescence
correlated with the corresponding class of anti-entactin anti-
body as measured by ELISA.
In addition, 51 of the total 305 patients had negative immu-
nofluorescence for immunoglobulin deposition along GBM.
Fifty of these patients had a negative ELISA for anti-entactin
antibodies.
Summary of the features of patients with anti-entactin anti-
bodies in the age group 18 to 30 years. Seventeen (42%) of the
patients with anti-entactin antibodies belonged to this age group
(Table 4). Females to males ratio was 2:1. Twelve patients
(70%) had primary glomerulonephntis with proliferative GN as
the predominating form, whereas five (30%) had secondary
glomerulonephritis, SLE predominating. Thirteen patients
(77%) had sub-nephrotic or nephrotic grade proteinuna, which
was progressive in eight of them, along with deterioration of
renal functions in eight patients. Two of them subsequently had
renal transplantation.
Discussion
Two distinct categories of patients with glomerulonephritis
possessing circulating IgG/IgM antibodies against entactin/ni-
dogen were identified in the present study.
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Table S. Extra-renal features in patients with anti-entactin antibodies
Age and Morphological Musculoskeletal Skin Eye Thyroid Neurological Gastro-intestinal &
sex Clinical diagnosis diagnosis symptoms rash symptoms involvement symptoms liver symptoms
30F SLE Proliferative ON + — — — — —
21F SLE Proliferative ON + — — — — .-
51F SLE Unclassified GN + — — — + —
55F SLE Non-representative + — — — — —
23F SLE Mesangiocapillary ON + — — — — —
24F SLE Unclassified ON + + — — + —
55F SLE Non-representative + + — — + —
32M SCTD-SLE-like Diabetic nephropathy + + — — — —
59M SCTD-SLE-like Tubulointerstitial + — — — — —
28F SCTD-SLE-like Extracapillary ON + — — — +
44F SCTD-SLE-like Mesangiocapillary GN + + — + — —
65M SCTD-unlike SLE Proliferative GN + + — — — —
59M Rheumatoid arthritis Proliferative GN + — — — — —
59M Systemic vasculitis Extracapillary GN + — + — — —
69F Systemic vasculitis Extracapillary ON + — — — —
76F Mesangiocapillary ON Mesangiocapillary ON — — + + — +
63F Proliferative GN Proliferative ON — — + + — +
40F Proliferative ON Proliferative ON + — — — — —
57F Proliferative GN Proliferative ON + — — — — —
43M Membranous ON Membranous ON + — — + — —
FIg. 4. Incidence of primary and secondary glomerulonephritis among
patients with anti-entactin antibodies. Symbols are: () other nephrop-
athies; (D) secondary ON; () primary ON.
One group consisted mainly of young patients (peak inci-
dence in the age group of 18 to 30 years) with primary
proliferative glomerulonephritis characterized by mesangial hy-
pertrophy and hyperplasia. Most of these patients had signifi-
cant proteinuria which was progressive or non-responsive to
immunosuppressive treatment in many cases, and was usually
associated with deterioration of renal functions leading to
uremia and subsequent renal transplantation in a few patients.
Although females exceeded males in this group, this difference
was largely due to the patients with SLE and not due to the
patient with primary glomerulonephntis that preponderated this
category of patients. The other group included patients in the
middle age group (tendency to peak in the age group 51 to 60
years) with mainly secondary glomerulonephritis having varied
types of morphological lesions. Most of the glomerulonephritis
in this age group were caused by systemic connective tissue
disorders, mainly SLE or SLE-like diseases. The disease was
usually milder in terms of proteinuria and renal function and
responded well to immunosuppressive therapy. Males and
females were equal in number.
There was no correlation between the class or titer of
anti-entactin antibodies with the type, severity or the progres-
sion of disease in either category.
On the other hand, a significant correlation was observed
between the deposition of IgG and 1gM antibodies along the
basement membrane as detected by direct immunofluorescence
and the corresponding class of anti-entactin antibody as mea-
sured by ELISA in the present study. Additionally, absence of
these antibodies on immunofluorescence was associated with
negative results on ELISA. This suggests, albeit indirectly, that
anti-entactin antibodies may, in some way, be involved in the
pathogenesis of certain forms of glomerulonephritis.
However, all these patients had granular deposition of immu-
noglobulins along the GBM on immunofluorescence and would
have traditionally been classified as having immune complex
diseases [4]. It is, nevertheless, an oversimplification to classify
them into immune complex or anti-GBM disease on the basis of
immunofluorescence findings.
The immunopathogenic mechanisms causing glomerulone-
phritides may not correlate with the immunofluorescence fea-
tures in certain conditions as has been shown in several animal
experiments [22, 231. The pattern of immunofluorescence pos-
sibly depends upon the location of target antigen in the GBM
rather than on the immunological mechanisms. In the classical
anti-GBM disease, Goodpasture syndrome, the target antigen
involved is present in the non-collagenous globular domain of
collagen IV of GBM which is located deeply embedded in the
collagen IV network and is practically immobile [12, 39].
Circulating antibodies directed against this antigen form corn-
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plexes which are uniformly distributed with no possibility to
reorganize, thereby giving a linear pattern on immunofluores-
cence. On the other hand entactin (nidogen), being a cell
binding protein, is located outside the collagen IV network [40]
and is relatively mobile, thus giving scope to the complexes
formed between the antibodies and entactin to reorganize and
give granular pattern.
The role of anti-entactin antibodies, however, in the patho-
genesis of glomerulonephritis cannot be inferred conclusively at
present. It is difficult to say whether these antibodies are the
direct cause of glomentlonephritides or just an epiphenomenon.
Moreover, whether the two categories of patients identified by
these antibodies are entirely different from each other or
represent the two extremes of a spectrum of a disease where on
one end are the young patients with primary glomerulonephri-
tis, while on the other there are the older patients with second-
ary glomerulonephritis caused by SLE or SLE-like diseases.
Interestingly, in contrast to the earlier belief, several studies
have shown that lupus nephritis may not result from the
deposition of immune complexes containing anti-DNA antibod-
ies [41—45]. Furthermore, in murine models of SLE it has been
demonstrated that anti-laminin and anti-RTE antibodies might
play a role in the pathogenesis of nephritis [23]. Moreover, it
has been observed that these antibodies are initially deposited
linearly along the GBM but later reorganize themselves into a
granular pattern [23]. This phenomenon possibly also exists in
human beings, but is difficult to elucidate since early and
repeated biopsies will be required to do so, which is ethically
questionable. Therefore, a pathogenic role of anti-GBM anti-
bodies should not be excluded on the grounds of a non-linear
glomerular immunofluorescence pattern.
In this context, a high incidence of the presence of anti-
entactin antibodies in the patients with SLE could insinuate
their involvement in the pathogenesis of lupus nephritis. This is
further supported by the fact that anti-entactin antibodies were
found in most of the patients with SLE or SLE-like nephritis
with positive ANA, while they were not very frequent in other
forms of collagen vascular diseases and in systemic vasculiti-
des. This would also mean that anti-entactin antibodies do not
result from non-specific inflammation or tissue destruction.
This is supported by our observation that these antibodies were
exceptionally rare in our control patients with inflammatory
diseases without renal involvement.
Concerning the other group of patients with primary prolif-
erative glomerulonephritis, it i noteworthy to observe that
anti-entactin antibodies were mainly present in primary mesan-
gio-proliferative glomerulonephritis. They were strikingly ab-
sent in IgA nephropathy, which resembles primary proliferative
glomerulonephritis morphologically, as well as in other non-
inflammatory conditions with profuse proteinuria like amyloi-
dosis, glomerulosclerosis, minimal change nephropathy and
diabetic nephropathy. Furthermore, their distribution among
other types of primary glomerulonephritides was sparse. Thus,
there was a significant overrepresentation of primary mesangio-
proliferative glomerulonephritis in young patients with anti-
entactin antibodies. This could very well represent a new
category of anti-GBM nephritis which, unlike the usual mesan-
gioproliferative glomerulonephritis or IgA nephropathy, have a
higher degree of proteinuria and an unpredictable or progres-
sive course. Incidently, this group of patients with anti-entactin
antibodies corresponds to a clinico-pathological entity identi-
fied by several groups as 1gM nephropathy [46, 47]. However,
the patients described under 1gM nephropathy had predominant
deposition of 1gM in mesangial region and only 50 to 60% of
them, in addition had membranous 1gM deposition. In our
study, we observed that all anti-entactin positive patients with
PGN had predominant 1gM deposition along GBM. In addition,
about 80% also had rrtesangial 1gM deposits. Moreover, about
90% of these patients had circulating 1gM anti-entactin antibod-
ies on ELISA. However, unlike in the above-mentioned studies
[46, 47], most of our patients had relatively severe renal disease
with a progressive course.
In conclusion, we propose that anti-entactin antibodies may
possibly be involved in the pathogenesis of certain forms of
glomerulonephritis (non-Goodpasture anti-GBM nephritis).
Since, one group of patients with anti-entactin antibodies com-
prises young individuals with a relatively severe and progres-
sive disease, identification of this category of patients would be
apt and perhaps relevant in their better management. More-
over, it will be of interest to study a large number of patients
with systemic connective tissue diseases to find out whether
anti-entactin antibodies are involved in nephritis of SLE and
related diseases.
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